共 50 条
Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C plus V): a pooled analysis
被引:0
|作者:
Lewis, K.
[1
]
Larkin, J.
[2
]
Ribas, A.
[3
]
Flaherty, K. T.
[4
]
McArthur, G. A.
[5
]
Ascierto, P. A.
[6
]
Dreno, B.
[7
]
McKenna, E.
[8
]
Zhu, Q.
[9
]
Mun, Y.
[8
]
Hauschild, A.
[10
]
机构:
[1] Univ Colorado, Comprehens Canc Ctr, Med, Aurora, CO USA
[2] Royal Marsden Hosp NHS Fdn Trust, Oncol, London, England
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[4] Massachusetts Gen Hosp, Med, Boston, MA 02114 USA
[5] Peter MacCallum Canc Ctr, Dept Med Oncol, East Melbourne, Australia
[6] Ist Nazl Tumori Fdn Pascale, Canc Immunotherapy & Innovat Therapy Unit, Melanoma, Naples, Italy
[7] Nantes Univ, Dermatol, Nantes, France
[8] Genentech Inc, Prod Dev, San Francisco, CA 94080 USA
[9] Genentech Inc, Oncol, San Francisco, CA 94080 USA
[10] Univ Hosp Schleswig Holstein, Dermatol, Kiel, Germany
关键词:
D O I:
暂无
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
1241P
引用
收藏
页数:1
相关论文